Michael Thompson, MD, PhD, is board certified in hematology and oncology. He is an active clinical researcher whose interests include hematologic or blood cancers (lymphoma, myeloma, leukemia and myelodysplastic syndrome). He is interested in developing new treatments for all cancers, particularly early phase (Phase I and II) molecular biomarker-driven clinical trials.
Dr. Thompson is the medical director for the Early Phase Cancer Research Program as well as the Oncology Precision Medicine Program. He is extensively published and serves as a reviewer and on the editorial board for multiple scientific publications.
Dr. Thompson is a member of the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR). He is currently on the National Cancer Institute (NCI) Lymphoma Steering Committee after rotating off the NCI Myeloma Steering Committee. He has also chaired the ASCO Research Community Forum and the ASCO Education Committee.
Mayo Medical School (Degree earned: MD, PHD)
Mayo School of Graduate Medical Education - Internal Medicine
Hematology - American Board of Internal Medicine
Internal Medicine - American Board of Internal Medicine
Medical Oncology - American Board of Internal Medicine
Hematology/Oncology - Univ of Texas MD Anderson Cancer Center (ACGME accredited)